



DOI: 10.4274/jcrpe.galenos.2025.2025-7-5

J Clin Res Pediatr Endocrinol 2026;18(2):261-272

# Challenges in Sex Assignment in 46,XX Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency and 11 $\beta$ -hydroxylase Deficiency in Developing Countries: Insights from an Expert Center in Indonesia

Irene Astrid Larasati<sup>1</sup>, Agustini Utari<sup>2,3</sup>, Annastasia Ediati<sup>4</sup>, Hedi L. Claahsen - van der Grinten<sup>5</sup>,  
 Tri Indah Winarni<sup>3</sup>

<sup>1</sup>Universitas Diponegoro Faculty of Medicine, Medicine and Health Study Program, Semarang, Indonesia

<sup>2</sup>Universitas Diponegoro Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Semarang, Indonesia

<sup>3</sup>Universitas Diponegoro Faculty of Medicine, Center for Biomedical Research, Semarang, Indonesia

<sup>4</sup>Universitas Diponegoro Faculty of Psychology, Semarang, Indonesia

<sup>5</sup>Radboud University Medical Centre, Amalia Children's Hospital, Department of Pediatrics, Division of Pediatric Endocrinology, Nijmegen, Netherlands

**Cite this article as:** Larasati IA, Utari A, Ediati A, Grinten HLCV, Winarni TI. Challenges in sex assignment in 46,XX congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 11 $\beta$ -hydroxylase deficiency in developing countries: insights from an expert center in Indonesia. J Clin Res Pediatr Endocrinol. 2026;18(2):261-272

## ABSTRACT

**Objective:** The absence of newborn screening, insufficient knowledge among medical professionals, and poor treatment adherence in congenital adrenal hyperplasia (CAH) in Indonesia causes late diagnosis. This study presents two decades of experience in gender assignment and diagnosis of 46,XX CAH.

**Methods:** A cohort study was carried out at a CAH referral center in Central Java, Indonesia. Data regarding clinical outcomes, molecular analysis, and sociodemographic information were taken from medical records. Participants were grouped based on current social gender, females and males. Gender at diagnosis, age at first presentation, age at first diagnosis, age at present, CAH types, virilization, puberty, birth attendant, and gender at birth decision maker significantly predict current gender identity.

**Results:** Among 131 individuals with 46,XX CAH, 52 (39.7%) with a sex assignment incongruent with their karyotype were included. The majority (49/52; 94.2%) had 21-hydroxylase deficiency (21OHD), while three (5.8%) had 11 beta-hydroxylase deficiency (11OHD). Individuals assigned as males at birth (3/52) had severe virilization. A change of gender occurred in 46 of 52 patients (88.46%). Midwives were the most frequent birth attendants (24/51), while pediatricians were the major decision-makers (19/51) of sex assignment.

**Corresponding Author:** Agustini Utari, MD, PhD, Universitas Diponegoro Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology; Universitas Diponegoro Faculty of Medicine, Center for Biomedical Research, Semarang, Indonesia

**E-mail:** agustiniutari@gmail.com **ORCID:** orcid.org/0000-0001-5965-1981

**Conflict of interest:** None declared

**Received:** 11.07.2025 **Accepted:** 30.09.2025 **Epub:** 24.10.2025 **Publication Date:** 01.07.2026



©Copyright 2026 by Turkish Society for Pediatric Endocrinology and Diabetes / The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. Licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

**Conclusion:** In Indonesia, many 46,XX individuals with CAH were initially assigned as males due to late diagnosis, primarily caused by low awareness among healthcare professionals and exacerbated by limited medical resources and a lack of clear guidelines on sex assignment. Therefore, targeted education and standardized guidelines involving a multidisciplinary team are crucial to ensure appropriate sex assignment and care.

**Keywords:** Congenital adrenal hyperplasia, sex assignment, developing country, newborn screening

### What is already known on this topic?

Gender assignment in virilized 46,XX congenital adrenal hyperplasia (CAH) is challenging, considering many interplaying factors, such as biological function, sociocultural factors, family beliefs, and psychological outcomes. In the absence of newborn screening, many CAH individuals are late-diagnosed, leading to various practices of gender assignment across countries. The lack of knowledge regarding CAH among healthcare professionals and the absence of newborn screening added to the complexity of gender assignment of CAH individuals in Indonesia.

### What this study adds?

This study presented the gender assignment practices in the only CAH center in Indonesia, highlighting the importance of timely and accurate CAH diagnosis to determine an optimal assignment for each individual. Moreover, the gender assignment approach of two types of CAH, 21-hydroxylase deficiency and 11 $\beta$ -hydroxylase deficiency, was presented.

## Introduction

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive conditions caused by enzymatic defects in steroid synthesis. Approximately 90-99% of CAH cases are caused by 21-hydroxylase deficiency (21OHD), although other causes include 11  $\beta$ -hydroxylase deficiency (11OHD), 17-hydroxylase deficiency (17OHD), *HSD3B2* deficiency, *CYP11A1* mutation, *STAR* mutation, and P450 oxidoreductase (POR) deficiency (1,2). Both 21OHD and 11OHD result in excessive adrenal androgen synthesis and cortisol deficiency leading to virilization of the external genitals in 46,XX individuals while 46,XY individuals are typically normal (3). CAH is the most frequent cause of 46,XX disorders/differences of sex development (DSD) (4).

The incidence of 21OHD (OMIM #201910) varies geographically and ethnically, with the highest rates in regions with a high degree of consanguinity. Globally, 1 in 14,000-18,000 live newborns are affected (5). 21OHD results from homozygous or compound heterozygous mutation in the *CYP21A2* genes manifesting as a clinical spectrum, from the most severe classic salt wasting (SW) type associated with cortisol and aldosterone deficiency to mild non-classic type (NCCAH), presenting with mild signs of hyperandrogenism (3). 11OHD (OMIM #202010), caused by mutations in the *CYP11B1* gene, is less common, accounting for approximately 0.2-8% of cases; hence the incidence is 1 in 100,000-200,000 live births (6,7). Similarly, 11OHD causes androgen excess, but aldosterone is unaffected. Instead, aldosterone precursors accumulate, leading to various degrees of hypertension (8).

Prenatal androgen exposure, particularly between 8-24 weeks of gestation and the early neonatal period, has long-lasting

organizational effects on neurobehavioral sexual differentiation, resulting in male-typical behavior in females with 21OHD or 11OHD (9). Increased androgen also causes various degree of virilisation in females (10). The Pediatric Endocrine Society (PES) advises female assignment in 46,XX CAH newborns to maintain fertility and reproductive functionality (11). However, recent studies propose male sex of rearing for severely virilized individuals, representing an evolving perspective considering both the importance of biological functional and psychosocial factors, including family dynamics, culture, prenatal androgen exposure, and sexual function, in accordance with the Chicago Consensus (12,13).

In many Western countries, newborn screening (NBS) has enabled early CAH diagnosis and intervention to prevent life-threatening adrenal crisis and minimizing comorbidities, such as short stature, infertility, and psychological adversity (14). Nevertheless, in many developing countries, CAH diagnoses remain delayed due to the absence of NBS (15,16). Furthermore, poor awareness among many healthcare professionals leads to confusion about gender assignment. Poor infrastructure and limited transportation in Indonesia, as well as parents' fear of stigmatization and educational barriers, further delay presentation to the healthcare facilities (17).

In Indonesia, birth attendants, which may include midwife, general physician, OB/GYN, pediatrician, or traditional midwife (*paraji*), assign sex primarily based on the external genital appearance. As only "male" or "female" is legally recognized in Indonesia, ambiguous genitalia present an additional burden. Physicians often suggested giving a unisex name to avoid delay in birth registration, which must occur within 60 days. The birth certificate is vital for civil status and state recognition,

according to the Constitution of 1945. In the past, many severely virilized, late-diagnosed 46,XX CAH had to undergo a legal trial to change their gender. As a Muslim majority country, the Indonesian Ulama Council (MUI) exerts a major influence on the management of DSD individuals by issuing a *fatwa*, a religious ordinance, that does not hold constitutional power but has a significant moral impact within the Muslim society, to prohibit transsexuals from having sex reassignment surgery, but legalized gender reassignment DSD (*khuntsa*) individuals. Although the MUI's fatwa is not legally binding, it significantly shapes court decisions and medical practices (18).

Gender assignment among DSD individuals is a complex process; hence, it is obligatory to involve a multidisciplinary team consisting of at least pediatric endocrinologists, surgeons or urologists, gynecologists, geneticists, psychologists and medical ethicists. Nevertheless, not all medical centers in Indonesia have applied this approach. It has caused various sex assignments and adverse psychological outcomes, including gender dysphoria, anxiety, stress, and depression, among these individuals. This study presents two decades of experience in gender assignment and diagnosis of 46,XX CAH individuals at a single CAH referral center in a developing country, emphasizing the importance of timely and accurate diagnosis to ensure appropriate treatment in future cases.

## Methods

### Research Design

A retrospective cohort study was conducted on patients referred to the CAH clinic in Semarang, Central Java. The patients' data were collected from medical records between July 2004-December 2024.

### Samples and Participants

All patients diagnosed by pediatric endocrinologists with CAH due to 21OHD based on clinical manifestations and 17-hydroxy progesterone (17-OHP) levels were included in this study. Patients with 11OHD CAH were diagnosed based on clinical manifestations and genetic test results. Patients with other etiologies of ambiguous genitalia were excluded.

### Data Collection

The following patients' data were obtained from medical records. The diagnosis of CAH was made by an experienced pediatric endocrinologist (AU) based on: (1) clinical manifestations, including genital ambiguity, vomiting, diarrhea, and failure to thrive; (2) biochemical analyses, including levels of 17-OHP; and (3) chromosomal analysis conducted in Center for Biomedical Research (CEBIOR), Faculty of Medicine, Universitas Diponegoro, Indonesia.

The diagnosis was confirmed by mutation analysis. DNA samples were sent to the Department of Human Genetics, Radboud University Medical Centre (Radboudumc), Nijmegen, the Netherlands, for multiplex ligation-dependent probe amplification and Sanger sequencing to analyze the *CYP21A2* gene and the *CYP11B1* gene for 21OHD and 11OHD CAH, respectively. If available, genetic evaluations were considered to confirm the type of CAH and to provide genetic counselling. In 11 individuals genetic tests were not conducted, thus, electrolyte levels, showing hyponatremia and hypokalemia, were considered to differentiate between CAH types, 21OHD and 11OHD, and a history of previous hospitalization for adrenal crisis for SW CAH.

### Sex Assignment

Patients presenting with a clinical suspicion of CAH, with symptoms that may have included vomiting, diarrhea, dehydration, failure to thrive, and virilization, were physically examined by a pediatric endocrinologist in our center. The degree of virilization and puberty were assessed using the Prader and Tanner stage, respectively. The patients would be referred for a biochemical investigation of electrolytes and 17OHP, to confirm CAH diagnosis. To determine the patient's karyotype, karyotyping was performed.

A psychological evaluation regarding gender assignment was not conducted for newborns, infants, and toddlers (<2 years) because the child had not developed a gender identity yet. The attending pediatric endocrinologist would explain the results and diagnosis. Based on the medical information provided by the pediatric endocrinologist, the parents made a decision regarding their child's gender.

A gender evaluation for children aged 2-7 years was conducted by a psychologist, who interviewed parents about the child's gender behavior, the child's gender preferences, and parental expectations regarding the child's gender. As gender development is dynamic and influenced by social factors, and considering the brain gender of the child, the psychologist will usually advise parents to continue observation of the child's gender behavior and preferences until adolescence, particularly concerning the possibility of the development of gender dysphoria. In most cases, girls with CAH developed masculine gender behavior and preferences, but without any confusion or dissatisfaction with the assigned gender. Children, adolescents, and adults who were late-diagnosed were referred for a psychological evaluation regarding gender assignment. A clinical psychologist and a psychiatrist conducted the assessment simultaneously and wrote a report independently to assess the individual's gender identity, gender role, and sexual orientation. Gender assignment of children aged 8 years or older was conducted using questionnaires and interviews with the patients and parents. If gender was doubted or matched with gender dysphoria according to the

DSM-5 criteria, typically triggered by the appearance of external genital or primary and secondary sexual characteristics, an interdisciplinary team meeting was held to discuss the results, outcomes, and planned management with consideration of the individual's overall well-being. A justification for gender change could not be made solely on gender behavior, such as clothing choices, playmates' preferences, and roles within a society. Instead, the individual's desire to be the opposite gender was the basis of the decision. The outcomes of the meeting, along with the consequences of choosing a certain gender, were delivered by the attending physician directly to the adult individuals and to the parents in the case of children and adolescents. Parents were given adequate time and space to make informed decisions in the best interest of their child. If a gender change was decided, it was a shared decision-making process between the team, patients, and parents.

CAH treatment was given immediately in 46,XX CAH patients assigned as females, i.e., patients with SW and simple virilizing (SV) type were given hydrocortisone (HC) combined with fludrocortisone (FC) for SW CAH and HC for SV CAH, respectively, whereas patients with 11OHD CAH were administered HC. Regular monitoring was conducted, consisting of gender satisfaction and disease evaluation control, which included signs of adrenal and SW crisis, reproductive health, and metabolic control (Figure 1).

Some of the individuals included in this study have already been reported by Ediati et al. (18) and Utari et al. (16), specifically, some who were reassigned as males and were siblings, respectively.

### Ethical Considerations

All parents or caregivers provided written informed consent prior to the study, and the Diponegoro University Faculty of Medicine Health Research Ethics Committee approved the study (approval no.: 682/EC/KEPK/FK-UNDIP/XII/2024, date: 19.12.2024), guaranteeing that it complied with the 1975 Declaration of Helsinki's ethical standards.

### Statistical Analysis

The categorization of the 46,XX CAH individuals were based on the current gender identity. Descriptive data are presented as frequency and percentages. Analysis was performed using SPSS, version 26.0 (IBM Corp., Armonk, NY, USA). Bivariate analysis using Fisher's exact test was conducted to determine the association between variables, including clinical characteristics and social factors. Statistical significance was defined as  $p$  value  $<0.05$ .

## Results

### Gender Assignment Practices

Among 131 46,XX 21OHD and 11 OHD patients managed in our center, 83 were assigned as female after birth, while 30 (22.9%)


individuals received sex assignments after birth inconsistent with the karyotyping result, and 18 (13.7%) individuals were undecided (Figure 2). There were 12 individuals (23.1%) who consented to be males and refused medication after receiving information regarding the CAH condition.

Six (11.54%) were late-diagnosed and identified themselves as males who chose not to take HC or FC. Two were diagnosed with SW CAH based on genetic test results. One individual was diagnosed at the age of 3 months and received treatment until the age of 1 year. He started to be re-treated at the age of 6 years, but his treatment was irregular. At the age of 8.5 years, a re-evaluation was conducted, and he wished to remain as a male. Another individual remained untreated/chose not to be treated and was assigned as male because his parents wanted a son despite a history of adrenal crisis. The parents had been fully informed about the impact of untreated CAH, which could be life-threatening. In addition, he had precocious puberty and attained skeletal maturity at the age of ten with a final height of 135.9 cm.

Upon diagnosis of CAH, three (5.77%) individuals initially assigned as females at birth refused to take medication and chose to live as males. Their gender was reassigned at the ages of 3, 7, and 45 years. One individual was assigned and reared as female, but at age 3 years transitioned to male due to social pressure regarding the appearance of the external genitals looking more like a male's. Another individual, originally assigned as female at birth, then independently transitioned and gained real-life experience as a male, visited the center only to confirm his gender. Later, he married a woman and reported a satisfying personal life.

From a total of 18 individuals whose gender was undecided at birth, three were siblings with 11OHD who were reassigned as males. They presented with severe virilization (Prader 5) at ages 1.7, 8.5, and 2.1 years; their gender was initially undecided but re-assigned as males after the diagnosis based on their father's decision and degree of virilization. Upon diagnosis, they refused to change their gender to female. They continued to live as men, had female partners, and were employed in physically demanding jobs, including construction work and driving.

The majority (49/52; 94.23%) had pathogenic *CYP21A2* variants, of which 43 (87.76%) had SW CAH. Three individuals had died after an adrenal crisis, after multiple hospitalizations due to frequent vomiting and dehydration. Almost half (24/51; 47.1%) of the CAH patients' births were attended by midwives, followed by OB/GYN (21/51; 41.2%) and traditional midwives (6/51; 11.8%). The largest proportion of sex assignments at birth were decided by pediatricians (19/51; 37.25%). The data on birth attendants and the person in charge of the birth sex assignment of one patient were not available in the medical record.




**Figure 1.** Flowchart of the sex assignment procedure of CAH individuals at our center

<sup>a</sup>Clinical suspicion of CAH includes vomiting, diarrhea, genital ambiguity, hyperpigmentation, and failure to thrive in newborns and infants. <sup>b</sup>Electrolytes, i.e., sodium, potassium, and chloride, and 17-OHP levels were measured. <sup>c</sup>Treatment comprised of hormonal, i.e., glucocorticoid and mineralocorticoid, and symptomatic, i.e., antihypertensive for 11OHD and NaCl for CAH SW. <sup>d</sup>Symptoms of adrenal insufficiency, menstrual cycle, libido and erection, sexual health, pubertal development, height, body mass index, blood pressure, bone age, and scrotal or ovarian ultrasound were monitored as indicated. <sup>e</sup>Psychological assessment of the individual's gender identity, gender role, and sexual orientation was conducted by a clinical psychologist and a psychiatrist. Reports were made independently. <sup>f</sup>A multidisciplinary team consisted of a pediatric endocrinologist, a geneticist, a clinical psychologist, a psychiatrist, a urologist, an OB/GYN, and a genetic counsellor. <sup>g</sup>Results were delivered to the patients and parents of children or adolescents. For adults, the results were received solely by them. <sup>h</sup>The gender decision was made by the parents considering the child's well-being. Adults with CAH made their own decision. 11OHD, 11 $\beta$ -hydroxylase deficiency; 17-OHP, 17-hydroxyprogesteron; CAH, congenital adrenal hyperplasia; MDT, multidisciplinary team.

## Predictors of Gender at Present

Table 1 shows a significant difference in age at diagnosis between females and males with 46,XX CAH, in which 87.5% of females (n=40) were diagnosed at age <1 year, compared to 8.3% in the male group (n=12) (p<0.001). In contrast to 62.5% females presenting with Prader 3, severely virilized individuals were significantly more likely to have male gender identity (p<0.008),

as evidenced by 41.7% and 25.0% males presenting with Prader 4 and 5, respectively. The involvement of healthcare professionals at the birth of CAH individuals significantly predicted their current gender (p<0.001), in which all females were attended by either a midwife or OB/GYN, and 54.5% of males were attended by non-healthcare professionals (i.e., traditional midwives). Due to the limited sample size, sensitivity analysis of the present gender subgroups was not conducted.



**Figure 2.** Gender assignment odyssey of 46,XX CAH individuals in Indonesia  
<sup>a</sup>CAH individuals who were reassigned as males gave informed consents not to take medication, i.e., HC and FC, due to their wish to remain as males.

## Discussion

Various gender assignment practices in CAH individuals remain common in Indonesia, even after two decades of experience. The majority of 46,XX CAH individuals in this study were late-diagnosed, which is comparable to a previous study in the context of lack of NBS for CAH (19). In Indonesia, the pilot project of CAH NBS only started in 2024 and expanded nationally at the beginning of 2025. Individuals who received earlier recognition were mostly attended by healthcare professionals, midwives and OB/GYN, and depicted an increasing tendency to be assigned

as females. According to the Decree of the Minister of Health, uncomplicated spontaneous birth was prioritized to be assisted in primary healthcare facilities, such as sub-district health centers (*Puskesmas*), midwife private practices, and primary doctor clinics, attended by midwives or general physicians (20). Although the Indonesian government increased the number of midwives at the community level and healthcare facilities in both urban and rural areas, only 55.2% of mothers sought help with childbirth from healthcare professionals, such as general physicians, midwives, hospitals, maternity homes, or other health centers (21). This indicates a significant reliance on non-medical professionals, including traditional midwives (*paraji*) who lack formal medical training.

The majority of 46,XX CAH individuals in Indonesia had the most severe SW type. Children with CAH were usually born with an uncomplicated pregnancy and spontaneous labor, hence, most children born in primary and secondary healthcare facilities were not immediately referred to the central hospital to receive an appropriate diagnosis and treatment. Referrals typically occurred after frequent episodes of vomiting and dehydration without improvement after receiving treatment, which are the characteristics of the most severe SW type (16,22,23). Delayed referral is a common challenge found in developing countries, as reported from Bangladesh, Sri Lanka, and Malaysia (24,25,26). Many Indonesian healthcare professionals lack knowledge about CAH, including the atypical presentation of external genital, clinical manifestation of adrenal insufficiency, genetic etiology, laboratory workup, and management (27). For example, genetics was only included in the list of midwives' standard competencies in 2020 (28).

Some 46,XX individuals with CAH were initially treated, but due to a lack of compliance, their conditions were poorly controlled. Upon monitoring, they were offered continuation of medication, but, despite understanding the impending adrenal crisis, chose not to take medication which may lower androgen levels, because they would like to remain as males. Our data showed that adherence to treatment remained an issue, despite the increased availability of CAH medications (29). CAH individuals in a developing country had to travel considerable distances and spend a substantial amount of time to receive care at the tertiary hospital (30). The need for lifelong medications might reduce individuals' motivation to adhere to treatment. Adding to the complexity were inadequate information and myths about the side effects of taking lifelong medications, which are commonly believed in developing countries (31,32). Conversely, a previous study in Sweden reported good treatment adherence in children and adults with CAH, with better adherence observed in SW, the most severe CAH (33).

<b>Table 1. Sex assignment practices in 46,XX CAH individuals</b>			
	<b>Current gender</b>		<b>p value</b>
	<b>Female n (%)</b>	<b>Male n (%)</b>	
<b>Sex at birth (n=52)</b>			0.064
Male	24 (60.0)	6 (50.0)	
Female	1 (2.5)	3 (25.0)	
Undecided	15 (37.5)	3 (25.0)	
<b>Gender at diagnosis (n=52)</b>			<b>0.004*</b>
Male	17 (42.5)	11 (91.7)	
Female	18 (45.0)	1 (8.3)	
Undecided	5 (12.5)	0 (0.0)	
<b>Age at first presentation (n=52)</b>			<b>&lt;0.001*</b>
<1 y	37 (92.5)	0 (0.0)	
1-5 y	2 (5.0)	3 (25.0)	
5-11 y	1 (2.5)	5 (41.7)	
11-18 y	0 (0.0)	2 (16.7)	
>18 y	0 (0.0)	2 (16.7)	
<b>Age at first diagnosis (n=52)</b>			<b>&lt;0.001*</b>
<1 y	35 (87.5)	1 (8.3)	
1-5 y	4 (10.0)	3 (25.0)	
5-11 y	1 (2.5)	4 (33.3)	
11-18 y	0 (0.0)	2 (16.7)	
>18 y	0 (0.0)	2 (16.7)	
<b>Age at present (n=46)</b>			<b>&lt;0.001*</b>
<1 y	33 (82.5)	0 (0.0)	
1-5 y	6 (15.0)	2 (33.3)	
5-11 y	1 (2.5)	3 (50.0)	
11-18 y	0 (0.0)	0 (0.0)	
>18 y	0 (0.0)	1 (16.7)	
<b>CAH types (n=52)</b>			<b>&lt;0.001*</b>
SW	39 (97.5)	4 (33.3)	
SV	1 (2.5)	5 (41.7)	
11OHD	0 (0.0)	3 (25.0)	
<b>Degree of virilization (n=52)</b>			<b>0.008*</b>
Prader 1	0 (0.0)	0 (0.0)	
Prader 2	2 (5.0)	1 (8.3)	
Prader 3	25 (62.5)	3 (25.0)	
Prader 4	13 (32.5)	5 (41.7)	
Prader 5	0 (0.0)	3 (25.0)	
<b>Puberty at diagnosis (n=52)</b>			<b>&lt;0.001*</b>
Yes	0 (0.0)	9 (75.0)	
No	40 (100.0)	3 (25.0)	

Table 1. Continued			
	Current gender		p value
	Female n (%)	Male n (%)	
<b>Treatment status (n=52)</b>			<b>&lt;0.001*</b>
Treated (hormonal treatment)	36 (90.0)	0 (0.0)	
Untreated	0 (0.0)	10 (83.3)	
Loss to follow-up	1 (2.5)	2 (16.7)	
Died	3 (7.5)	0 (0.0)	
<b>Birth attendant (n=51)†</b>			<b>&lt;0.001*</b>
Midwife	20 (50.0)	4 (36.4)	
OB/GYN	20 (50.0)	1 (9.1)	
Traditional midwife ( <i>paraji</i> )	0 (0.0)	6 (54.5)	
<b>Decision maker of gender at birth (n=51)††</b>			<b>0.011*</b>
Midwife	12 (30.0)	4 (36.4)	
OB/GYN	2 (5.0)	0 (0.0)	
Pediatrician	18 (45.0)	1 (9.1)	
General physician	1 (2.5)	0 (0.0)	
Traditional midwife ( <i>paraji</i> )	0 (0.0)	3 (27.3)	
Parents	7 (17.5)	3 (27.3)	
<b>Genetic variants (n=82)§</b>			
R356W	53.1	13.6	
I2G	28.1	31.8	
Exon 1-7 del	6.3	0.0	
P30L	6.3	0.0	
W22X	3.1	0.0	
p.Trp406*	3.1	0.0	
p.Trp20*	0.0	4.5	
I172N	0.0	4.5	
Exon 1-3 del	0.0	4.5	
p.Ile386del	0.0	4.5	
p.Gln196*	0.0	4.5	
R356W/Microconversion in the promoter region (c.-126T; c.-113G>A; c.-110T>C; c.-103A>G) [~80% less active transcript]	0.0	4.5	
p.Val252fs (CYP11B1)	0.0	27.3	
<p>*Statistically significant (p&lt;0.05)                      ‡There were 6 individuals who were assigned male at birth and stayed as males.                      †Puberty was determined by pubarche (Tanner P2).                      †Data were unavailable from 1 male patient due to loss to follow-up.                      ††Data were unavailable from 1 male patient due to loss to follow-up.                      §Allele frequency was calculated from the genetic test results of 41 individuals. Allele frequency was presented in percentage. No comparative analysis for the allele frequency variable was conducted.                      ¶Individuals were siblings. Their father decided their sex based on the male-like appearance of their external genitalia.                      N/A: not available; 11OH: 11 β -hydroxylase deficiency; CAH: congenital adrenal hyperplasia; SV: simple virilizing; SW: salt wasting.</p>			

Individuals with CAH in developing countries missed receiving timely diagnosis and treatment. The lack of laboratory analysis facilities in Indonesia, especially outside of Java, hindered diagnosis in our cohort. With prolonged time to diagnosis, CAH individuals were exposed to extended periods of elevated androgen levels which affected permanent neural organizational changes in the brain and, as a consequence, caused male-typical behaviors and toy choices in females with CAH (34). The masculinization effect from the androgen persisted and played a role in the establishment of male gender identity in 46,XX CAH (35). Therefore, after thorough evaluation with a clinical psychologist, individuals diagnosed in childhood or beyond determined to remain males owing to the androgen masculinizing effect on their gender behavior and identity. This finding was in accordance with a prior study that illustrated a mid-childhood conversion to male in late-diagnosed 46,XX CAH individuals in Bangladesh (36). In contrast, transition to male in 46,XX individuals with CAH has rarely been reported in developed countries due to early diagnosis and adequate access to medication. Nevertheless, this presented a complex situation because assigning a 46,XX CAH individual as male could deprive them of the opportunity of having children; the reproductive function would be preserved in 46,XX CAH females who were treated promptly and appropriately (3).

Gender identity issues and distress were commonly observed in DSD individuals, which led to gender dysphoria (37). Late-identified DSD individuals have reported experiencing more emotional and behavioral issues, including social isolation, particularly in adult women (38). Compared to children with DSD who were raised as boys, those who were raised as girls showed a high level of gender confusion. The same study also reported that women with DSD who received no treatment exhibited behavior inconsistent with their gender roles and were presumably more dissatisfied with their gender identity (18). Findings from some Sri Lankan and Indian 46,XX CAH populations revealed that a subset of individuals raised as females had gender dysphoria (25,39). Nonetheless, a meta-analysis found that the prevalence of gender identity issues was higher in CAH-raised males compared to females (40).

The majority of 46,XX CAH individuals reassigned as female were diagnosed before the age of one year. At this age, the primary social interactions were within the family where parents had the strongest impact on gender role development in their children (41). Later, children start forming stereotypes for both sexes at the age of two to three years, where they begin socializing beyond the family (42). Social stereotypes and pressure may influence the child's emerging gender identity, as seen in one of the individual within the "assigned male and remained as male" group.

However, a study by Dessens (43) revealed that some previously misassigned females with CAH at birth had difficulty with society's acceptance of gender reassignment. This was aggravated by preconceived notions and fear of social rejection. These stereotypes of how someone should behave to conform to a certain gender increased the burden on females with CAH, particularly if they were late-diagnosed and priorly assigned as males. In some cases, societal values further complicate the decision of gender assignment. In our society that prefers male children over females, some parents still choose to raise their 46,XX child as a male, even after diagnosis. Having a son was considered superior to having a daughter because, although a male is infertile, he can still hold a high place in a community and get a better job compared to a female. This was a common practice in Indonesia as patriarchal beliefs were still held by many, especially in rural areas (44).

Most 46,XX CAH in our cohort came with a moderate to severe degree of virilization (Prader 3-5), and more than half were assigned as male at birth. The appearance of external genitalia had a great impact on the gender assignment process, in which Prader 1-3 were more likely to be assigned females, but Prader 4-5 were apt to be assigned males, particularly due to the complexity of feminizing surgery, which may include worse outcomes, more complications, and greater assessment challenges (45). Both DSD and controls in a study by Chowdhury et al. exhibited a more masculine identity when they had more severely virilized external genitalia (46).

The development of one's gender is a fluid process with various factors interplaying, including potential for future fertility, hormonal therapy, feminizing or masculinizing surgery, psychological implications, and sociocultural factors (3). The latter were very diverse between populations, hence an individualized and measured approach needs to be considered (15,24,25,44). In the CAH Clinical Guidelines, an infant born with 46,XX CAH should be assigned female. This recommendation was made reflecting the condition in developed countries where early diagnosis was possible due to the availability of NBS (5). Previous studies reported that male assignment in 46,XX CAH could be an option in severely masculinized individuals, as they showed a good quality of life (QoL) (12). An emphasis on social and cultural preferences needed to be considered in assigning a person's gender, for example in Middle and Far Eastern countries, where males were considered to have a higher status than females (47). According to the Clinical Guidelines for the Management of Disorders of Sex Development in Childhood, the management of a person with a DSD condition must be individually tailored. A patient-centered care approach from a multidisciplinary team should consider the uniqueness of each person; hence, the best decision needs to be made in the patient's best interest (48). A psychologist or a psychiatrist trained in DSD care played an

integral part in gender assignment or reassignment, decision regarding surgery or hormonal treatment, and assessment of short or long-term outcomes. However, the DSD multidisciplinary team was only available in Semarang, Indonesia, bringing challenges to the provision of holistic and comprehensive care for the patients and their families (49).

Due to its potential to be life-threatening, CAH must be ruled out in every child born with genital ambiguity, and the attendants should contact healthcare professionals familiar with the disease. Although genital ambiguity is present only in 46,XX CAH, male gender assignment was common in a region without NBS (5). Several studies reported that only a small portion of severely virilized 46,XX CAH raised females reported dissatisfaction with their gender. Stigmatization related to cross-gender behavior and atypical physical appearance has been identified as a stress predictor in both adults with DSD and parents of children with DSD (23). In India, DSD individuals were labelled as “*hijra*” and received discrimination, which resulted in lower QoL (50). In developing countries, fertility and future marriage remained a concern for parents of female CAH (30).

A guideline for sex assignment in CAH individuals in Indonesia has not been established. The beginning of CAH NBS in Indonesia in 2025 represents a significant advance, offering a promising opportunity for early identification and treatment for affected individuals, thereby anticipating serious outcomes such as adrenal crisis, delayed sex assignment, and gender dysphoria. Nevertheless, national CAH guidelines for sex assignment need to be established. Furthermore, the development of effective education strategies for healthcare professionals will improve the knowledge and skills of healthcare professionals regarding CAH. Thus, its implementation should be made at primary, secondary, and tertiary care levels. Future research on the long-term evaluation of the psychological and social impact of late diagnosis should be conducted in resource-limited settings.

### Study Limitations

This was a descriptive study in a single national DSD referral center, but it can provide useful insights into the past and changing practice concerning individuals with CAH. This study relied on retrospective data, which may be affected by incomplete medical records. Moreover, findings from a single referral center may not fully represent the sex assignment practices of CAH individuals in Indonesia. This study was not able to report the impact of sex assignment on the CAH individuals. Hence, future studies are needed to provide broader insights into CAH sex assignment practices in developing countries.

### Conclusion

Various sex assignment practices affecting 46,XX CAH individuals in Indonesia remain, caused by low awareness among healthcare

professionals and a lack of laboratory facilities, leading to late diagnosis. Gender at diagnosis, age at first presentation, at first diagnosis, and at gender reassignment, types of CAH, degree of virilization, puberty status, state of treatment, birth attendant, and decision maker for gender at birth were significant predictors of gender at present. Treatment compliance issues exposed these individuals to excessive androgen levels, causing male-gender behavior. Cultural, religious, and family values played an important role in shaping gender identity. In Indonesia, development of national CAH sex assignment guidelines and targeted education for healthcare professionals is necessary to ensure better long-term outcomes for individuals affected by CAH.

#### Ethics

**Ethics Committee Approval:** Diponegoro University Faculty of Medicine Health Research Ethics Committee approved the study (approval no.: 682/EC/KEPK/FK-UNDIP/XII/2024, date: 19.12.2024).

**Informed Consent:** All parents or caregivers provided written informed consent prior to the study.

#### Acknowledgements

The authors would like to thank the lab specialist at Center for Biomedical Research (CEBIOR), Faculty of Medicine, Universitas Diponegoro for providing the invaluable data for this study. The authors would also want to express gratitude toward the Program Magister menuju Doktor untuk Sarjana Unggul (PMDSU) Ministry of Education and Culture Republic Indonesia scholarship program for granting the support for this study.

**Presented in:** Part of the manuscript was presented at the 3rd InaSHG (the Indonesian Society of Human Genetics) Conference and the 2<sup>nd</sup> ISGC (the Indonesian Society of Genetic Counselors) Annual Meeting at Malang on the 22<sup>nd</sup> of November 2024. The authors declare that the manuscript has not been previously published in any scientific journal or other publication outlet.

#### Footnotes

#### Authorship Contributions

Concept: Irene Astrid Larasati, Agustini Utari, Tri Indah Winarni, Design: Irene Astrid Larasati, Agustini Utari, Tri Indah Winarni, Data Collection or Processing: Irene Astrid Larasati, Agustini Utari, Annastasia Ediaty, Analysis or Interpretation: Irene Astrid Larasati, Agustini Utari, Annastasia Ediaty, Hedi L. Claahsen - van der Grinten, Tri Indah Winarni, Literature Search: Irene Astrid Larasati, Agustini Utari, Writing: Irene Astrid Larasati, Agustini Utari, Annastasia Ediaty, Hedi L. Claahsen - van der Grinten, Tri Indah Winarni.

**Financial Disclosure:** Program Magister menuju Doktor untuk Sarjana Unggul (PMDSU) Ministry of Education and Culture Republic Indonesia scholarship program (no: 601-81/UN7.D2/PP/VI/2024).

### References

1. Wang C, Tian Q. Diagnostic challenges and management advances in cytochrome P450 oxidoreductase deficiency, a rare form of congenital adrenal hyperplasia, with 46, XX karyotype. *Front Endocrinol (Lausanne)*. 2023;14:1226387.

2. Finkelstein GP, Vieites A, Bergadá I, Rey RA. Disorders of sex development of adrenal origin. *Front Endocrinol (Lausanne)*. 2021;12:770782.
3. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenström A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA, White PC. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. *Endocr Rev*. 2022;43:91-159.
4. Alkhzouz C, Bucerzan S, Miclaus M, Mirea AM, Miclea D. 46,XX DSD: developmental, clinical and genetic aspects. *Diagnostics (Basel)*. 2021;11:1379.
5. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SE, White PC. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018;103:4043-4088.
6. White PC. Steroid 11 beta-hydroxylase deficiency and related disorders. *Endocrinol Metab Clin North Am*. 2001;30:61-79.
7. Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 11 $\beta$ -hydroxylase deficiency. *Endocrine*. 2017;55:19-36. Epub 2016 Dec 7
8. Reisch N, Högler W, Parajes S, Rose IT, Dhir V, Götzinger J, Arlt W, Krone N. A diagnosis not to be missed: nonclassic steroid 11 $\beta$ -hydroxylase deficiency presenting with premature adrenarche and hirsutism. *J Clin Endocrinol Metab*. 2013;98:e1620-e1625. Epub 2013 Aug 12
9. Lagunas N, Fernández-García JM, Blanco N, Ballesta A, Carrillo B, Arevalo MA, Collado P, Pinos H, Grassi D. Organizational effects of estrogens and androgens on estrogen and androgen receptor expression in pituitary and adrenal glands in adult male and female rats. *Front Neuroanat*. 2022;16:902218.
10. Kung KTF, Louie K, Spencer D, Hines M. Prenatal androgen exposure and sex-typical play behaviour: a meta-analysis of classic congenital adrenal hyperplasia studies. *Neurosci Biobehav Rev*. 2024;159:105616. Epub 2024 Mar 5
11. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. *J Clin Endocrinol Metab*. 2002;87:4048-4053.
12. Mazur T, O'Donnell J, Lee PA. Extensive literature review of 46,XX newborns with congenital adrenal hyperplasia and severe genital masculinization: should they be assigned and reared male? *J Clin Res Pediatr Endocrinol*. 2024;16:123-136. Epub 2023 Dec 27
13. Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. *Arch Dis Child*. 2006;91:554-563. Epub 2006 Apr 19
14. de Hora M, Heather N, Webster D, Albert B, Hofman P. The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives. *Front Endocrinol (Lausanne)*. 2023;14:1226284.
15. Adriaansen BPH, Utari A, Westra D, Juniarto AZ, Ariani MD, Ediati A, Schröder MAM, Span PN, Sweep FCGJ, Drop SLS, Faradz SMH, van Herwaarden AE, Claahsen-van der Grinten HL. 46,XX males with congenital adrenal hyperplasia: a clinical and biochemical description. *Front Endocrinol (Lausanne)*. 2024;15:1410122. <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1410122>
16. Utari A, Faradz SMH, Ediati A, Rinne T, Ariani MD, Juniarto AZ, Drop SLS, van Herwaarden AE, Claahsen-van der Grinten HL. Challenges in the treatment of late-identified untreated congenital adrenal hyperplasia due to CYP11B1 deficiency: lessons from a developing country. *Front Endocrinol (Lausanne)*. 2022;13:1015973.
17. Septiono W. Equity challenges in Indonesian health care. *Lancet Glob Health*. 2023;11:e646-e647.
18. Ediati A, Juniarto AZ, Birnie E, Drop SL, Faradz SM, Dessens AB. Gender development in Indonesian children, adolescents, and adults with disorders of sex development. *Arch Sex Behav*. 2015;44:1339-1361. Epub 2015 Mar 27
19. Lebovitz RM, Pauli RM, Laxova R. Delayed diagnosis in congenital adrenal hyperplasia. Need for newborn screening. *Am J Dis Child*. 1984;138:571-573.
20. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1354/2022 Tentang Petunjuk Teknis Penggunaan Dana Jaminan Persalinan Tahun Anggaran 2022. HK.01.07/MENKES/1354/2022 Aug 23, 2022.
21. Octavius GS, Daleni VA, Sagala YDS. An insight into Indonesia's challenges in implementing newborn screening programs and their future implications. *Children (Basel)*. 2023;10:1216.
22. Juniarto AZ, Ulfah M, Ariani MD, Utari A, Faradz SM. Phenotypic variation of 46,XX late identified congenital adrenal hyperplasia among Indonesians. *J ASEAN Fed Endocr Soc*. 2018;33:6-11. Epub 2018 Mar 12
23. Ediati A, Juniarto AZ, Birnie E, Okkerse J, Wisniewski A, Drop S, Faradz SMH, Dessens A. Social stigmatisation in late identified patients with disorders of sex development in Indonesia. *BMJ Paediatr Open*. 2017;1:e000130.
24. Biswas R, Kamrul-Hasan AB, Rahman SN. Congenital adrenal hyperplasia: experience from Dhaka Shishu (Children) Hospital, Bangladesh. *Mymensingh Med J*. 2024;33:1075-1080.
25. Seneviratne SN, Sandakelum U, Jayawardena CH, Weerasinghe AM, Wickramarachchi PS, de Silva S. Presenting status of children with classical congenital adrenal hyperplasia over two decades (1999-2018) in the absence of newborn screening in Sri Lanka. *J Pediatr Endocrinol Metab*. 2021;34:1131-1137.
26. Raja Bongsu RH, Khalid K, Razali WAD, Zainal Abidin N, Saiful Nizam NAI, Rahidin NA, Apparow S, Habib A. Congenital adrenal hyperplasia testing in the Malaysian population: real-world data sourced from a national reference laboratory. *Malays J Pathol*. 2024;46:247-257.
27. Faradz SMH, Listyasari N, Utari A, Ariani MD, Juniarto AZ, Santosa A, Ediati A, Rinne TK, Westra D, Claahsen-van der Grinten H, de Jong FH, Drop SLS, Ayers K, Sinclair A. Lessons learned from 17 years of multidisciplinary care for differences of sex development patients at a single Indonesian center. *Sex Dev*. 2023;17:170-180. Epub 2023 Sep 12
28. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/320/2020 Tentang Standar Profesi Bidan. HK.01.07/MENKES/320/2020 May 15, 2020. <https://file.bbg.ac.id/cabinet/ministerial-regulation/2020/Kepmenkes-Nomor-320-Tahun-2020.pdf>
29. Armstrong K, Benedict Yap A, Chan-Cua S, Craig ME, Cole C, Chi Dung V, Hansen J, Ibrahim M, Nadeem H, Pulungan A, Raza J, Utari A, Ward P. We all have a role to play: redressing inequities for children living with CAH and other chronic health conditions of childhood in resource-poor settings. *Int J Neonatal Screen*. 2020;6:76.
30. Zainuddin AA, Grover SR, Soon CH, Ghani NAA, Mahdy ZA, Manaf MRA, Shamsuddin K. A multicenter cross-sectional study of Malaysian females with congenital adrenal hyperplasia: their body image and their perspectives on feminizing surgery. *J Pediatr Adolesc Gynecol*. 2020;33:477-483. Epub 2020 May 4
31. Pulungan AB, Fadiana G, Annisa D. Type 1 diabetes mellitus in children: experience in Indonesia. *Clin Pediatr Endocrinol*. 2021;30:11-18. Epub 2021 Jan 5
32. Qanitha A, Qalby N, Amir M, Uiterwaal CSPM, Henriques JPS, de Mol BAJM, Mappangara I. Clinical cardiology in South East Asia: Indonesian lessons from the present towards improvement. *Glob Heart*. 2022;17:66.

33. Ekblom K, Strandqvist A, Lajic S, Hirschberg AL, Falhammar H, Nordenström A. Assessment of medication adherence in children and adults with congenital adrenal hyperplasia and the impact of knowledge and self-management. *Clin Endocrinol (Oxf)*. 2021;94:753-764. Epub 2021 Jan 3
34. Ristori J, Cocchetti C, Romani A, Mazzoli F, Vignozzi L, Maggi M, Fisher AD. Brain sex differences related to gender identity development: genes or hormones? *Int J Mol Sci*. 2020;21:2123.
35. Savaş-Erdeve Ş, Aycan Z, Çetinkaya S, Öztürk AP, Baş F, Poyrazoğlu Ş, Darendeliler F, Özsu E, Şıklar Z, Demiral M, Unal E, Özbek MN, Gürbüz F, Yüksel B, Evliyaoglu O, Akyürek N, Berberoğlu M. Clinical characteristics of 46,XX males with congenital adrenal hyperplasia. *J Clin Res Pediatr Endocrinol*. 2021;13:180-186. Epub 2020 Dec 30
36. Chowdhury TK, Laila K, Hutson JM, Banu T. Male gender identity in children with 46,XX DSD with congenital adrenal hyperplasia after delayed presentation in mid-childhood. *J Pediatr Surg*. 2015;50:2060-2062. Epub 2015 Aug 28
37. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-5*. American Psychiatric Association; 2013.
38. Ediati A, Faradz SM, Juniarto AZ, van der Ende J, Drop SL, Dessens AB. Emotional and behavioral problems in late-identified Indonesian patients with disorders of sex development. *J Psychosom Res*. 2015;79:76-84. Epub 2014 Dec 15
39. Gangaher A, Jyotsna VP, Chauhan V, John J, Mehta M. Gender of rearing and psychosocial aspect in 46 XX congenital adrenal hyperplasia. *Indian J Endocrinol Metab*. 2016;20:870-877.
40. Babu R, Shah U. Gender identity disorder (GID) in adolescents and adults with differences of sex development (DSD): a systematic review and meta-analysis. *J Pediatr Urol*. 2021;17:39-47. Epub 2020 Nov 12
41. Krishna S, Thomas TM, Sreekumar S. Gendered parenting and gender role attitude among children. *Cult Psychol*. 2025;31:940-959.
42. Martin CL, Ruble DN. Patterns of gender development. *Annu Rev Psychol*. 2010;61:353-381.
43. Dessens A. Gender assignment and identity in DSD. *Rev Esp Endocrinol Pediatr*. 2023;14(Suppl 2): 39-47.
44. Utari A, Silberkasten M, Musa S, Hassan S, Sharma R, Bramer W, van der Zwan YG, Drop SLS. Global perspective of psychosocial care of patients with differences of sex development from low-income countries. *J Reprod Infant Psychol*. 2025;43:366-384. Epub 2024 Dec 18
45. Cera G, Corsello A, Novizio R, Di Donna V, Locantore P, Paragliola RM. Severe hyperandrogenism in 46,XX congenital adrenal hyperplasia: molecular physiopathology, late diagnoses, and personalized management. *Int J Mol Sci*. 2024;25:11779.
46. Chowdhury TK, Chowdhury MZ, Mili F, Hutson JM, Banu T. Gender identity shows a high correlation with Prader score in patients with disorders of sex development (DSD) presenting in mid childhood. *Pediatr Surg Int*. 2014;30:527-532. Epub 2014 Feb 25
47. Lee PA, Wisniewski AB, Baskin L, Vogiatzi MG, Vilain E, Rosenthal SM, Houk CP. Advances in diagnosis and care of persons with DSD over the last decade. *Int J Pediatr Endocrinol*. 2014;2014:19.
48. Cools M, Nordenström A, Robeva R, Hall J, Westerveld P, Flück C, Köhler B, Berra M, Springer A, Schweizer K, Pasterski V; COST Action BM1303 working group 1. Caring for individuals with a difference of sex development (DSD): a consensus statement. *Nat Rev Endocrinol*. 2018;14:415-429.
49. Maritska Z, Saputro ED, Pangestu R, Faulinza E, Sakinah M, Pranandita F, Satopoh FA, Ridwan I, Amalia S. Current status of disorders of sexual development in Indonesia. *Adv Hum Biol*. 2022;12:210-213.
50. Majumder A, Roychaudhuri S, Chakraborty S, Bhattacharjee K. An observational study of the quality of life among gender incongruent individuals from "Hijra" community of India. *Indian J Endocrinol Metab*. 2020;24:301-305. Epub 2020 Aug 27